Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool

Eline Picavet1*, David Cassiman2, Bert Aertgeerts3,4 and Steven Simoens1

Abstract

Background: Rare diseases are defined as life-threatening or chronically debilitating diseases with a prevalence of 50 out of 100,000 individuals or less. Orphan medicinal products (OMPs) are intended for the treatment of rare diseases. The assessment of quality of evidence in small populations is often complex. Many generic tools are unfit. Therefore, the aim of this study was to develop and validate a new tool to assess the quality of OMPs’ clinical evidence (COMPASS).

Methods: Firstly, a draft version of the COMPASS tool, developed by the authors and consisting of three parts, was amended based on suggestions obtained in four rounds of expert consultation. Secondly, the tool was put through three rounds of validation. The data source was information provided on the Orphanet website and in European Public Assessment Report (EPAR) document of the European Medicines Agency.

Results: The first pilot round revealed a high (92.2%) inter-rater agreement for part one of the tool. After further improvements, the final inter-rater agreement was 86.4% for part two (on methodological quality) and three (on quality of reporting) of the tool. The COMPASS tool does not attempt to score or rank the quality of clinical evidence, but rather to give an outline of various, key elements with respect to quality of clinical evidence of OMP studies.

Conclusions: The COMPASS tool can be applied to assess the quality of evidence of an OMP based on information in the registration dossier, for example by local reimbursement agencies, pharmacists or clinicians. In that way, the tool can contribute to making reimbursement and/or treatment decisions increasingly more founded on the principles of evidence-based decision making.

Keywords: Quality assessment, Quality assessment tool, Quality of reporting

Background

Rare diseases are defined as life-threatening or chronically debilitating diseases with a prevalence of 50 out of 100,000 individuals or less [1]. It is estimated that there are currently between 5,000 and 7,000 rare diseases [2]. Orphan medicinal products (OMPs) are intended for the treatment of rare diseases [1]. Studies to evaluate the effect of an OMP in patients with rare diseases are often hampered by the difficulty of enrolling a sufficient number of patients [3,4]. For example, N-acetylglutamate synthase (NAGS) deficiency is a very rare disorder that can cause neonatal life-threatening hyperammonemia. To date, only few patients with NAGS deficiency have been identified. In Europe, treatment with carglumic acid for NAGS deficiency has been authorized based on efficacy data from four case reports and 12 patients in a retrospective data collection study [5,6]. For some OMPs, it is clear that the quantity of clinical evidence cannot be obtained. Even so, achieving the highest quality of evidence should still be aimed for [7]. But how do we define quality of clinical evidence? According to GRADE (Grading of Recommendations Assessment, Development and Evaluation), quality of evidence reflects the extent of our confidence that the

* Correspondence: eline.picavet@farm.kuleuven.be
1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, PO box 521, Leuven 3000, Belgium
Full list of author information is available at the end of the article

© 2013 Picavet et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
estimates of an effect are correct [8]. Traditionally, randomized controlled studies are regarded as the gold standard in achieving high quality of evidence whereas case controls or case studies are considered of lesser, but not lacking, value [7,9,10]. Nevertheless, high quality evidence is needed to guide clinical decision-making [11].

The assessment of quality of evidence in small populations at the time of registration and/or reimbursement is often complex. However, the rising number of authorized OMPs and their increased use in clinical practice emphasizes the need for an objective assessment. Quality assessment involves evaluation of a study’s validity, i.e. the degree to which its design, conduct and analysis have minimised biases or errors [12]. In general, there are three ways to assess the quality of studies: individual markers, checklists and scales [13-15]. Many generic tools, from simple checklists to extensive questionnaires, are currently used to assess studies [12,16]. However, the majority of these instruments are unfit to assess clinical studies of OMPs, as they do not take into consideration the difficulties (i.e. small sample size, use of surrogate endpoints, etc...) that are inextricably bound up with these studies. According to Khan, new tools can be developed, keeping in mind that all components of the tool should be selected with due consideration for its purpose. These components should capture both generic methodological issues and issues specific to the subject under review [12].

Therefore, the aim of this study was to develop and validate a new tool, COMPASS (Clinical evidence of Orphan Medicinal Products – an ASSeessment tool), to assess the quality of OMPs clinical evidence that is presented for OMPs at the time of marketing authorization in the EU.

Methods
Design of the tool
The design of the tool was conceptualised after consulting the Centre for Evidence-Based Medicine (CEBAM), Leuven, Belgium. A draft version of the tool was drawn up based on elements derived from existing checklists supplemented with items specifically related to rare diseases and OMPs [13-15].

Validity of the COMPASS tool
The draft version of the tool was proofread by two laymen to increase readability. Subsequently, four expert consultations were organised with six experts (in a two-two-one-one fashion) with a view to increasing content validity (Table 1). All consultations were audio-taped and transcribed verbatim. The transcripts were analyzed in three steps. The first step was aimed at familiarizing with the data by reading and re-reading the transcripts. Secondly, a framework of key issues was identified. Finally, all issues were grouped according to the framework and interpreted. The draft version of the tool was adapted in accordance with all relevant issues, as deemed upon consensus by the researchers, raised at all consultations.

Data source
The data source of the tool consisted only of information provided on the Orphanet website and in European Public Assessment Report (EPAR) and/or the Scientific Discussion (SD) document prepared by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA). These documents provide information about chemical, pharmaceutical, biological, toxico-pharmacological and clinical aspects of a drug [5]. For practical and privacy reasons, we did not have access to the original documents submitted to EMA. However, we anticipated that the publicly EPARs sufficiently reflect these original documents. The assessment of the methodological quality was restricted to studies that were described as ‘pivotal’ or ‘main’ clinical studies. The analyses were performed per study, as opposed to per orphan medicinal product, due to possible methodological differences between the studies. No additional data from publications of those studies was used due to possible unsystematic reporting and publication bias.

Consistency of the COMPASS tool
A first pilot round was undertaken, in which five randomly selected OMPs (i.e. one from each “type”: betaine anhydrous (one indication, only literature reports), histamine dihydrochloride (one indication, open label study), idursulfase (one indication, RCT), pirfenidone (one

---

Table 1 Overview of expert consultations

| Expert consultation #1 | Background       |
|------------------------|------------------|
| E.P.                   | Academic         |
| S.S.                   | Academic         |
| Expert 1               | Physician - Regulatory |
| Expert 2               | Academic - Regulatory |

| Expert consultation #2 | Background       |
|------------------------|------------------|
| E.P.                   | Academic         |
| S.S.                   | Academic         |
| D.C.                   | Academic - Physician |
| Expert 3               | Pharmaceutical industry |
| Expert 4               | Hospital pharmacist |

| Expert consultation #3 | Background       |
|------------------------|------------------|
| E.P.                   | Academic         |
| Expert 5               | Academic         |

| Expert consultation #4 | Background       |
|------------------------|------------------|
| E.P.                   | Academic         |
| Expert 6               | Academic - Regulatory |
section, two RCTs) and sorafenib (two indications, two RCTs) were analysed by two raters (E.P. and S.S.). The two raters completed all three parts of the COMPASS tool. A second pilot round was undertaken, in which four alphabetically successive OMPs (ziconotide, agalsidase alfa, sildenafil citrate and lenalidomide) were analysed by two raters (E.P. and D.C.). One rater completed all three parts of the tool, whereas the other completed the second and third part. The final version (Additional file 1) of the COMPASS tool was drawn up in accordance with the issues raised during the two pilot rounds.

The COMPASS tool consists of three parts; the first part collects general descriptive information about the OMP and its marketing authorization. The second part focuses on the assessment of the methodological quality (i.e. specifically related to study design, patient and study population, control arm, blinding, randomization and allocation, outcomes, adherence and statistical analysis) of the study. The last part assesses the quality of reporting. The Orphanet website was consulted to provide information on the prevalence of the rare disease in which the indication is authorized and its therapeutic need [2]. The registration of the pivotal studies on EudraCT and/or clinicaltrials.gov was evaluated on their respective websites [17,18].

In a third and final round, two raters (E.P. and S.S.) completed the tool for a sample of OMPs (n = 29). One rater (E.P.) completed all three parts of the tool, whereas the other (S.S.) completed the second and third part. Additionally, expertise in the medical field was believed necessary to answer the question “Is the duration of the study relevant to the natural history of the disease?”. Therefore, a third rater (D.C.) (i.e a trained physician) also answered this question for all 29 OMPs. Upon disagreement between the raters, the assessment of D.C. was considered decisive.

In all three rounds, raters completed the tool independently and once-only. Additionally, raters were blinded with respect to results of others. The same information was available to all raters. After data collection, E.P. was responsible for comparison of the results.

Analysis
All analyses (including the calculation of inter-rater agreement, by percent agreement calculation) were performed using MS Office Excel 2010.

Results
Validity of the COMPASS tool
During the expert consultations, a number of issues were discussed related to both the design (for example, on the sub-classification of the tool into three parts) and to the content of the tool (for example, on how to define a valid method of randomization). The total number of issues discussed per consultation is shown in Table 2. All relevant suggestions were implemented.

Consistency of the COMPASS tool
The inter-rater agreement rates of the three rounds are shown in Table 3. In the first round, the overall inter-rater agreement was 87.1%. Also, there were small anomalies (i.e when one rater answered ‘No’ and the other answered ‘Not reported’) for 3.7% of the answers. There was a slight increase in inter-rater agreement in the second round. Additionally, there was less (1.6% of the answers) confusion between ‘No’ and ‘Not reported’. However, this rate increased to 6.2% in the third round. In all rounds, disagreements between the raters were able to be resolved upon reviewing the data.

All three raters independently evaluated the relevance of the study duration with respect to the natural history of the disease. There was agreement between three raters for 65.4% of the studies. In case of disagreement, the rater with a medical background was more inclined to assess the study duration as appropriate (77.8%) than raters without a medical background (E.P. 27.8% and S.S. 22.2%). Additionally, the raters without a medical background experienced more difficulties in evaluating study duration, as shown by their choice of “Don’t know” respectively nine and two times.

Discussion
The goal of this research was to develop and validate a new tool COMPASS to assess the quality of OMPs clinical evidence presented at the time of marketing authorization in the EU. The COMPASS tool (Additional file 1) does not attempt to score or rank the quality of clinical evidence, but rather to give an outline of various, key elements with respect to quality of clinical evidence, as seen by experts. Ultimately, it is up to the evaluator to define minimum conditions of quality for an individual OMP or a set of similar OMPs. Ideally, these conditions should be defined without taking into account unmet need and disease severity, as these are not determining factors for quality of clinical evidence.

This COMPASS tool can be applied to assess the quality of evidence of an OMP based on the information in the registrations dossiers, for example by local reimbursement agencies for the review of clinical evidence or

| Table 2 Expert consultation - number of issues discussed |
|---------------------------------------------------------|
| Expert consultation #1 | 44  |
| Expert consultation #2 | 53  |
| Expert consultation #3 | 48  |
| Expert consultation #4 | 42  |
The COMPASS tool has several strengths and weaknesses. The tool was developed after iterative rounds of expert consultation and underwent several pilot rounds to increase its validity. The tool assesses the level of clinical evidence that is presented in the pivotal studies at the time of marketing authorization. As such, it does not take into consideration the evidence in any of the supporting studies or evidence generated as part of post-marketing commitments. Adding data from publications would allow for quality control of the EPAR data, but was considered outside the scope of this study. Also, the tool is dependent on the quality of reporting in the EPAR and/or SD documents. Finally, a general medical knowledge of the rater is advisable to complete the tool. Additional check boxes (‘Don’t know’ and ‘Not reported’) were provided, to account for possible problems related to these last issues.

Conclusions
In conclusion, we developed and validated a new tool for the assessment of clinical evidence of OMPs. The COMPASS tool can for example be used by local reimbursement agencies for the review of clinical evidence from OMP registration dossiers or by clinicians and pharmacists upon considering a (new) treatment. Furthermore, we hope that the COMPASS tool can initiate and add to the open debate on study standards for orphan medicinal products. In that way, the COMPASS tool can contribute to making reimbursement decisions increasingly more founded on the principles of evidence-based decision making.

Additional file

Additional file 1: COMPASS tool.

Abbreviations
COMPASS: Clinical evidence of orphan medicinal products – an assessment tool; OMP: Orphan medicinal product; EPAR: European public assessment report; FDA: Food and drug administration; SD: Scientific discussion; CHMP: Committee for human medicinal products; EMA: European medicines agency.

Competing interests
The authors declare that they have no competing interests. No sources of funding were used to assist in the preparation of this manuscript.

Authors’ contributions
The work presented was carried out in collaboration between all authors. EP, SS, DC and BA were involved in the initiation of the project and the design of the methods. EP, SS and DC actively participated in the expert consultations and in the data collection. EP analysed the data and interpreted the results. EP, SS, DC and BA discussed the results. EP and SS wrote the draft paper. SS, DC and BA revised the draft paper. All authors have read and approved the final manuscript.

Table 3 Inter-rater agreement

| Inter-rater agreement (%) | Overall | Part 1 | Part 2 | Part 3 |
|---------------------------|---------|--------|--------|--------|
| 1st pilot round (n = 5)   | 87.1    | 92.2   | 76.9   |        |
| 2nd pilot round (n = 4)   | NA      | NA     | 77.5   |        |
| 3rd round (n = 29)        | NA      | NA     | 86.4   |        |

n, number of orphan medicinal products under review; NA, not applicable.
Acknowledgements
No sources of funding were used to assist in the preparation of this manuscript. The authors would like to thank the expert panel – Bogaert M., Cleemput I., De Nys K., Dooms M., Hulstaert F. and Tambuyzer E. – for their valuable comments and suggestions to improve the tool.

Author details
1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, PO box 521, Leuven 3000, Belgium. 2Department of Hepatology, University Hospital Leuven, Herestraat 49, Leuven 3000, Belgium. 3Department of General Practice, KU Leuven, Kapucijnenvoer 33, PO box 7001, Leuven 3000, Belgium. 4Belgian Centre for Evidence-Based Medicine, Leuven, Belgium.

Received: 25 June 2013 Accepted: 5 October 2013
Published: 9 October 2013

References
1. Commission E. Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. Off J Euro Comm 2000, L18:1–5.
2. Orphanet - The portal for rare diseases and orphan drugs. www.orpha.net.
3. Wilcken B: Rare diseases and the assessment of intervention: what sorts of clinical trials can we use? J Inherit Metab Dis 2001, 24:291–298.
4. Tambuyzer E: Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010, 9:821–829.
5. European Medicines Agency. www.ema.europa.eu/ema/.
6. Haberle J: Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther Clin Risk Manag 2011, 7:327–332.
7. Day S: Evidence-based medicine and rare diseases. Rare Dis Epidemiol 2010, 686(1):1–53.
8. Balshem H, Feldman M, Schunemann HJ, Oxman AD, Kurz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH: GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011, 64:401–406.
9. Barton S: Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. BMJ 2000, 321:255–256.
10. Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA: Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009, 96:20–26.
11. Knerr MC, Steiner RD: The role of evidence-based medicine and clinical trials in rare genetic disorders. Clin Genet 2008, 74:197–207.
12. Undertaking systematic reviews of research on effectiveness. http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds D, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1–12.
14. Deeks JJ, D’Amico R, Soward AJ, Sakarovitch C, Song F, Petticrew M, Altman DG: Evaluating non-randomised intervention studies. Health Technol Assess 2003, 7iii:173.
15. De Chantars A, Charles P, Hopewell S, Ravaud P, Altman DG: Reviews assessing the quality or the reporting of randomized controlled trials are increasing over time but raised questions about how quality is assessed. J Clin Epidemiol 2011, 64:136–144.
16. Olivio SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ: Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 2008, 88:156–175.
17. EUdraCT. http://eudraact.ema.europa.eu/.
18. ClinicalTrials.gov. clinicatrials.gov/.
19. Heron L, Laurensen S, Costello J, Anderl C, Knoppe J: Gaining reimbursement of orphan products in Europe: challenges Due to wide variations in evidence requirements and processes. Value in Health 2012, 15:A309.
20. Jeffery M, White R: Orphan drug pricing and access - current situation and future trends in Eu. Value in Health 2012, 15:A309.
21. Food and Drug Administration: Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.
22. European Medicines Agency: Guideline on the evaluation of anticancer medicinal products in man. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500037128.pdf.
23. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stoup DF: Improving the quality of reporting of randomized controlled trials - The CONSORT statement. JAMA 1996, 276:637–640.

Cite this article as: Picavet et al.: Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool. Orphanet Journal of Rare Diseases 2013 8:157.